Levodropropizine Syrup Manufacturing: Key Considerations for Pharma Companies

Oral liquid syrups are among the most technically demanding pharmaceutical dosage forms to manufacture consistently, and antitussive-antihistamine combination syrups add an additional layer of formulation complexity that separates capable manufacturing partners from commodity contract fillers.

A levodropropizine 30mg + chlorpheniramine maleate 2mg per 5ml combination syrup is not simply a matter of dissolving two APIs in a sweetened aqueous base and filling into bottles. Both active ingredients have defined pH sensitivity profiles. The preservative system must remain effective across the product's 24-month shelf life. Viscosity must be maintained within a validated range to ensure dose accuracy with each measured 5ml spoonful. And the organoleptic properties taste, colour, clarity directly determine patient compliance, particularly in paediatric and elderly populations who form a significant proportion of this product's end users.

For pharma brand managers and CMO procurement teams evaluating manufacturing partners for this formulation, this guide covers the key technical, quality, and commercial considerations that determine whether a syrup manufacturer can reliably deliver a product that performs as intended at the patient level.

For clinical context on what this combination treats and how it works, see our complete guide on levodropropizine and chlorpheniramine maleate syrup uses.

1. pH Control — The Stability Foundation of Both APIs

Both levodropropizine and chlorpheniramine maleate have optimal stability ranges within specific pH windows, and the formulation pH must be carefully controlled to satisfy both simultaneously.

Levodropropizine is most stable in a mildly acidic environment — degradation rates increase significantly at pH above 6.5, where hydrolysis of the carbamate functional group begins to accelerate. Chlorpheniramine maleate is also most stable in acidic conditions and shows increased degradation at pH above 6.

The formulation must therefore be buffered to maintain pH within a validated range — typically 4.5 to 6.0 — throughout manufacturing, filling, and the full 24-month shelf life. This requires:

• Selection and validated concentration of a pharmaceutical-grade buffer system (citrate or acetate buffers are common for this pH range)
• Inline pH monitoring during high-shear mixing to confirm pH is within specification before proceeding to filling
• pH testing at each stability timepoint to confirm the buffer system is maintaining the target pH under real-time and accelerated storage conditions

A manufacturer who does not have inline pH monitoring capability during syrup manufacturing, or who does not include pH in their batch release CoA, is producing a product whose chemical stability cannot be assured across the shelf life.

2. Viscosity Control — Dose Accuracy at the Patient Level

The viscosity of a pharmaceutical oral syrup directly determines how accurately a patient or caregiver can measure a 5ml dose using a standard measuring spoon or oral dosing syringe.

A syrup that is too thin (low viscosity) pours quickly, making controlled measurement difficult and increasing the risk of over-dosing — particularly relevant for a combination containing chlorpheniramine maleate, where excess dose contributes to the sedative effect that patients and prescribers want managed. A syrup that is too thick (high viscosity) pours slowly, clings to the spoon, and may not fully transfer to the patient's mouth — contributing to under-dosing and treatment failure.

The validated viscosity range for a 30mg + 2mg per 5ml antitussive-antihistamine syrup is established during formulation development and must be controlled through:

• Consistent sourcing and concentration of viscosity-modifying excipients (typically hydroxypropyl methylcellulose or sorbitol in this formulation class)
• Viscosity testing during in-process quality checks at the mixing stage before filling
• Viscosity included in the batch release Certificate of Analysis with specification limits

Ask prospective manufacturers to show you the viscosity specification from their batch release CoA for a recent batch of this or a comparable oral syrup formulation.

3. Preservative Efficacy Testing — Microbiological Quality Across the Shelf Life

An oral syrup is an aqueous formulation — water activity is high, and microbiological contamination risk is significantly greater than for solid oral dose forms. The preservative system must maintain microbial limits within IP/USP specification not at the time of manufacture alone but throughout the 24-month shelf life under ambient storage conditions.

Preservative efficacy testing (PET) — conducted per IP/USP/BP antimicrobial effectiveness testing protocols — challenges the preservative system with defined inocula of test organisms (Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, Aspergillus brasiliensis) and measures the log reduction in viable organism count at defined time intervals. The formulation's preservative type and concentration must produce the required log reductions within the timeframes specified by the relevant pharmacopoeia.

For a cough and allergy syrup that may be stored in a household bathroom cabinet — an environment with elevated humidity, variable temperature, and repeated bottle opening — preservative efficacy at the end of the validated shelf life is as important as at the time of manufacture. Confirm that any prospective manufacturer includes PET data in their stability programme and that the validated preservative system has been tested at accelerated and real-time conditions.

4. High-Shear Mixing and Homogeneity — Ensuring Dose Uniformity

Levodropropizine and chlorpheniramine maleate must be completely dissolved in the syrup base with no undissolved API particles — as this is a solution formulation, not a suspension. Both APIs must be uniformly distributed through the bulk syrup such that every 5ml dose drawn from the bottle contains the full declared 30mg + 2mg.

This requires:

• A validated dissolution and mixing sequence — the order in which APIs and excipients are added to the mixing vessel, and the mixing speed and duration, must be documented and followed identically for every batch
• High-shear mixing capability — to achieve complete dissolution of APIs and uniform distribution of excipients including the viscosity modifier, sweetening agents, and colouring
• In-process sampling at multiple points in the mixing vessel to confirm API content uniformity in the bulk before filling begins
• HPLC assay of both APIs on the finished batch — not estimated from API input weights, but measured analytically in the filled product

A manufacturer whose batch release CoA shows only a single pooled assay with no in-process uniformity data is not providing the analytical evidence that dose consistency across the batch has been confirmed.

5. 100ml Amber Glass Bottle — Pack Integrity and Light Protection

Chlorpheniramine maleate is light-sensitive — prolonged exposure to UV and visible light accelerates degradation of the antihistamine component, reducing potency over the shelf life. The standard pack format — amber glass or amber PET bottle with a child-resistant, tamper-evident closure — provides both light protection and physical integrity for an aqueous formulation.

When evaluating manufacturers, confirm:

• Whether amber glass or amber PET bottles are used, and what the validated light transmission specification is for the container
• Whether the bottle closure has been validated for child resistance to the relevant standard (IS 9510 or equivalent)
• Whether the tamper-evident seal and labelling are included in the batch packing record as inspected parameters
• What the validated headspace oxygen specification is, and whether nitrogen blanketing is used during filling to minimise oxidative degradation of the APIs

6. GMP Compliance and Regulatory Documentation

The GMP certified cough syrup manufacturer India you partner with must hold a valid WHO-GMP certificate with scope explicitly covering oral liquid syrup manufacturing — not only solid oral dosage forms. The manufacturing licence under the Drugs and Cosmetics Act must also cover the product category.

For third-party manufacturing, confirm that the manufacturer can provide:

• Process validation report — at least three consecutive commercial-scale batches demonstrating that the process consistently produces a product of defined quality
• Cleaning validation report — documenting removal of API residues between product changeovers in shared manufacturing equipment
• Stability data — accelerated (40°C/75% RH, 6 months) and real-time (25°C/60% RH or 30°C/65% RH, 24 months) for the specific formulation
• Batch documentation package — BMR, BPR, in-process check records, and signed CoA delivered with every commercial batch

7. CMO Service Model for Antitussive-Antihistamine Syrup

For pharma brands entering the respiratory antitussive market — whether for prescription channel, OTC, or PCD franchise distribution — the CMO service model matters as much as technical capability.

A capable manufacturing partner should offer:

• Private labelling and artwork compliance — label design meeting Schedule P requirements for antihistamine and antitussive syrups, including mandatory sedation warning text for chlorpheniramine-containing products
• Batch size flexibility — MOQ compatible with franchise launch volumes, with scale-up capability as the brand grows
• Supply reliability SLA — documented lead time and batch failure replacement protocol in the manufacturing agreement
• Export documentation support — if the brand's distribution extends beyond India, the manufacturer should be able to support product registration documentation for target export markets

Conclusion

Choosing a manufacturing partner for a levodropropizine and chlorpheniramine maleate combination syrup is a decision that determines your product's chemical stability, microbiological quality, dose accuracy, and regulatory standing across its commercial life. The seven considerations in this guide — pH control, viscosity, preservative efficacy, high-shear mixing uniformity, pack integrity, GMP compliance, and CMO service model — are the complete framework for a procurement evaluation that protects both your brand and your end patients.

The GMP certified cough syrup manufacturer India Delwis Healthcare, produces levodropropizine + chlorpheniramine maleate syrup at our WHO-GMP certified Ahmedabad facility — with inline pH monitoring, validated high-shear mixing, HPLC dual-API batch release, preservative efficacy testing, and full regulatory documentation support. Our antiasthmatic and antiallergic range and broader syrup and oral liquid manufacturing capabilities — alongside complementary formulations including sucralfate and oxetacaine suspension and esomeprazole and domperidone capsules — give brand partners a single sourcing point for a complete respiratory and GI pharmaceutical portfolio.

This article is written for pharmaceutical industry professionals and B2B procurement teams. It is intended for informational and educational purposes within the pharmaceutical manufacturing and sourcing context.